Chosa Oncology
0.825
SEK
Less than 1K followers
CHOSA
Spotlight Stock Market
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
+3.12%
+21.32%
+18.19%
-1.55%
+21.32%
-22.17%
-97.67%
-93.22%
-93.87%
Chosa Oncology, Danish -Swedish biotechnology company, has developed the iCIP platform, which includes a liposomal formulation of cisplatin (LiPlaCis) and the companion diagnostic (DRP) tool detecting patients who benefits the most of the cisplatin treatment. The recently achieved clinical phase 2b results mean that the Company is now gearing up the business development activities to find partners for partnership or trade deal.
Read moreMarket cap
58.53M SEK
Turnover
-
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
30/5
2025
Interim report Q1'25
13/6
2025
General meeting '25
29/8
2025
Interim report Q2'25
All
Press releases
ShowingAll content types
Notice of annual general meeting in Chosa Oncology AB
Chosa Oncology AB: CHOSA- Extending CHOSA's Platin DRP: Predicting Carboplatin Efficacy in Breast Cancer
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools